arrow Log In to View Account     |          

Thursday, April 20th at 7:00 PM ET

Presenters: Kavita V. Nair, PhD (Chair)
and Daniel Kantor, MD, FAAN

This webcast will provide live credit (L) for those states requiring it.

While there are now more than a dozen disease-modifying therapies (DMTs) for patients with multiple sclerosis (MS) available, the cost of DMTs continues to grow, potentially impeding access to care. Generic and biosimilar DMTs have the potential to substantially reduce drug-related expenses and promote adherence to therapy for patients living with MS. Currently, there is only 1 generic DMT, generic glatiramer acetate (GA). The structural complexity of GA has resulted in misconceptions regarding the bioequivalence between the generic and innovator molecule and precludes the use of the cost-saving generic therapy in clinical practice. Specialty and managed care pharmacists have unique roles as pharmacotherapy experts, key formulary decision makers and, in many cases, healthcare providers who have direct contact with patients with MS. This live webcast will provide pharmacists with the information necessary to enhance their role in the management of patients with MS, particularly with assessing the appropriate utilization of generic agents.

The goal of this educational activity is to provide an in-depth understanding of generic and biosimilar DMTs so that specialty and managed care pharmacists can implement strategies to improve access to DMTs for their patients with MS and reduce healthcare costs.

This educational initiative is intended for specialty and managed care pharmacists, as well as other pharmacists interested in the management of patients MS. No prerequisites required.

  • Activity Overview and Goals
  • Overview of DMTs
  • Considerations for FDA Approval of MS Generics and Biosimilars
  • Approved Generic DMTs: GA
  • Investigational Generic and Biosimilar DMTs in MS
  • Pharmacist-Driven Strategies to Overcome Barriers to DMT Access
  • Conclusions and Postassessment
The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. Upon the conclusion of this activity, the participant should be able to:
  • ASSESS the potential of generic and biosimilar DMTs to reduce the financial burden associated with MS.
  • COMPARE the FDA approval process for generic, non-biological complex drugs and biosimilar agents as it relates to MS DMTs.
  • EVALUATE data regarding therapeutic equivalence of approved and investigational generic and biosimilar DMTs.
  • IMPLEMENT pharmacist-driven strategies to improving access to MS DMTs and reduce healthcare costs.
Kavita V. Nair, PhD (Chair)
Center for Pharmaceutical Outcomes Research
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado Anschutz Medical Campus
Aurora, Colorado

Daniel Kantor, MD, FAAN
Kantor Neurology
President Emeritus
Florida Society of Neurology
Coconut Creek, Florida

acpe logoThe University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this application-based activity will provide a statement for 1.5 live contact hours credit (0.15 CEUs). Successfully completing the activity and receiving credit includes: 1) attending the session; 2) watching, listening to, and participating in the activity; 3) completing the self-assessment instrument with a score of at least 70%. A statement of CE credit will available for download following successful completion of the educational activity. UAN: 0064-0000-17-210-L01-P. CE credit will be submitted to the NABP CPE Monitor within 30 days. It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted..

NABP e-PROFILE ID NUMBER: Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website:
To receive credit for your participation in this activity, all pharmacists must include their NABP e-Profile ID number, along with their month and date of birth. If incorrect information is provided, this will result in "rejected" status from the CPE Monitor. It is the responsibility of the participant to notify The University of Tennessee (within the 60 day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.

Please allow up to 30 days for your credit to appear on CPE-Monitor.

It is the policy of The University of Tennessee College of Pharmacy that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during the presentation(s). Detailed disclosures will be made in the presentations.

A participant, provider, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity provided or coprovided by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

There is no fee for this educational activity.

<img src="" alt="procced to pretest" border="0" />
University of Tennessee Advanced Studies in Pharmacy (ISSN-1558-0350), is published by ASiM CE, LLC, d/b/a ASiM, PO Box 340, Somerville, NJ 08876. (908) 253-9001. Copyright ©2017 by ASiM CE, LLC. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of ASiM CE LLC.